Customizing mRNA is easy, and that's what makes it the next frontier for personalized medicine − a molecular biologist explains 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
Alpha, beta, theta: what are brain states and brain waves? And can we control them? 
Eggs from men, sperm from women: how stem cell science may change how we reproduce 
Doing science in Antarctica has harmed an environment under great pressure. Here's how we can do better 
The brightest object in the universe is a black hole that eats a star a day 
Larger and more frequent solar storms will make for potential disruptions and spectacular auroras on Earth 
Archeoastronomy uses the rare times and places of previous total solar eclipses to help us measure history 
Why some people don't trust science – and how to change their minds 
Spacesuits need a major upgrade for the next phase of exploration 
Six space missions to look forward to in 2024 
Tatahouine: 'Star Wars meteorite' sheds light on the early Solar System 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
Dark energy is one of the biggest puzzles in science and we're now a step closer to understanding it 
How do airplanes fly? An aerospace engineer explains the physics of flight 
Despite the advancement of science and technology that the world has seen through the past decades, cancer diagnoses remains a piece of very heavy news to whoever receives it. Humanity has yet to find the ultimate cure for cancer. For now, however, there have been successful researches and clinical trials that spark people’s hope such as the case for a Colorado resident.
CBS Denver recently reported that Cañon City resident Karl Leason marks his second year of remission from acute myeloid leukemia (AML) this month. He joined the clinical trial led by Dr. Daniel Pollyea of the University of Colorado’s School of Medicine and Director of Leukemia Services. Dr. Pollyea was testing a cocktail of medications composed of azacitidine and venetoclax to treat AML stem cells.
When Leason was diagnosed with cancer, he was reportedly told he had six months to one year left in his life. However, all that obviously changed after joining Dr. Pollyea’s program. The UC associate professor explained, “This treatment is getting down to the roots. It’s going down and eradicating the root cause of the disease.” Dr. Pollyea also sounded very hopeful saying, “We do have some cases in which we believe it’s possible these patients have been cured.”
The same report noted that Leason is not the only success story of Dr. Pollyea’s research. The program saw a 91 percent remission rate among adult patients who were recently diagnosed with cancer.
While scientists around the world are still hard at work to develop a complete cure for cancer, various organizations are hoping to help patients get the best treatment approach possible. Another research by scientists from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation also reported promising results from antibody drug that targets deadly tumors from the inside.
The drug is being called tisotumab vedotin or TV. It finds its way into the tumor and kills the cancer cells from within. The research has been published on the Lancet Oncology and claimed that some patients battling late stages of cancer of the ovary, bladder, lungs, and cervix had responded well to the trial.
